Brief: Akebia Therapeutics Announces Positive Top-Line Results Of Phase 4 Impact Study Of Auryxia® (Ferric Citrate) For In-Center And Home Dialysis Patients
29/06/2023 14:31
June 29 (Reuters) - Akebia Therapeutics Inc AKBA.O :
* AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS OF
PHASE
4 IMPACT STUDY OF AURYXIA® (FERRIC CITRATE) FOR IN-CENTER AND
HOME DIALYSIS PATIENTS
* AKEBIA: TREATMENT WITH AURYXIA RESULTED IN STATISTICALLY
SIGNIFICANT DIFFERENCE IN MEAN MONTHLY ESA USE, NON-SIGNIFICANT
DIFFERENCE IN MEAN MONTHLY IV IRON USE
* AKEBIA THERAPEUTICS INC: THREE PATIENTS STOPPED AURYXIA
DUE TO
GASTROINTESTINAL INTOLERANCE OR ADVERSE EVENTS IN STUDY
* AKEBIA THERAPEUTICS INC: SERIOUS ADVERSE EVENTS OCCURRED
IN 39%
OF PATIENTS RECEIVING AURYXIA AND 59% IN THOSE RECEIVING SOC
Source text for Eikon: ID:nPn2CQFX3a
Further company coverage: AKBA.O
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule